Browsing Tag
HMPL-A830
2 posts
GSK bets up to $1.3bn on HUTCHMED’s preclinical KRAS-EGFR cancer therapy
GSK will pay HUTCHMED $110 million upfront and up to $1.185 billion in additional milestones for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR conjugate expected to enter human trials later in 2026.
GSK licenses HUTCHMED’s HMPL-A830 cancer therapy in deal worth up to $1.295bn
GSK plc has licensed HUTCHMED’s experimental KRAS-EGFR cancer therapy HMPL-A830 for up to $1.295 billion, giving the Chinese biotech a $110 million upfront payment before the drug enters its first human trial.